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Abstract 
Recent findmgs have elucidated the mechanism for clearance from the extracellular space of the two types of plasmmogen activators, urokmase-type 
plasmmogen activator (u-PA) and tissue-type plasmmogen activator (t-PA), and their type-l mhlbltor (PAI-1) ActlvatorlPAI-1 complexes and 
uncomplexed t-PA bmd to the multdlgand receptors a,-macroglubuhn receptor/low density hpoprotem receptor-related protein (a,MR) and eplthehal 
glycoprotem 330 (gp330) These receptors mediate endocytosls and degradation of u-PAIPAI-1 complex bound to the glycosyl phosphatldyl 
mosltol-anchored urokmase receptor (u-PAR) on cell surfaces, and partlclpate, m cooperation with other receptors, m hepatuz clearance of 
actlvator/PAI-1 complexes and uncomplexed t-PA from blood plasma The a,MR- and gp330-mediated ndocytosls of a hgand (u-PA/PA&l complex) 
mltlally bound to another receptor (u-PAR) 1s a novel kmd of interaction between membrane receptors Bmdmg to cc,MR and gp330 IS a novel kmd 
of molecular ecogmtlon of serme protemases and serpms 
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1. Introduction: the plasminogen activation system 
The extracellular formation of the serme protemase 
plasmm from the zymogen plasmmogen is catalysed by 
either one of two other serme protemases, the urokinase- 
type plasmmogen activator (u-PA) and the tissue-type 
plasmmogen activator (t-PA). u-PA-catalysed plasmin 
generation is implicated m events involvmg pencellular 
proteolysis, like tissue remodelhng, cell migration and 
invasion, and m activation of growth factors (reviewed 
in [l-3]). t-PA-catalysed plasmm generation is active pri- 
marily m fibrinolysis (reviewed m [4-61). 
u-PA IS released from cells as a angle-chain zymogen, 
pro-u-PA, which is converted to the active two-chain 
enzyme by lirmted proteolysis (reviewed m [l]) t-PA is 
also released from cells as a angle-chain form; but smgle- 
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Abbrewattons a,M, a*-macroglobuhn, a MR, a,-macroglobuhn recep- 
tor/low density hpoprotem receptor related protem, RAP, a,-mac- 
roglobulm receptor-associated protein, EGF, epldermal growth factor, 
gp330, eplthehal glycoprotem 330, GPI, glycosyl phosphatldyl mosltol, 
PAI-1, type-l plasmmogen activator mhlbltor, PAL2, type-2 plasmmo- 
gen activator mhlbltor, t-PA, tissue-type plasmmogen activator, u-PA, 
urokmase-type plasmmogen activator, u-PAR, urokmase receptor 
chain t-PA has a measurable activity, although it IS about 
50-fold lower than that of its two-chain counterpart (re- 
viewed m [5]) Both activators contam a C-termmal 
serme protemase domain (the B-chain) and an N-ternn- 
nal A-chain, contammg m t-PA a fibronectm-type II 
finger domain, an epidermal growth factor (EGF) do- 
mam and two krmgles, and m u-PA an EGF domain and 
a krmgle (reviewed m [I]; Fig 1A) 
The glycosyl phosphatidyl mositol(GPI)-anchored 
u-PA receptor (u-PAR) binds to the N-terminal growth 
factor domain of u-PA. u-PAR contams 3 homologous 
domains, the N-termmal one bemg hgand bmdmg (Fig. 
1 B). u-PAR serves to accelerate pro-u-PA activatton and 
localize plasmmogen activation to cell surfaces (reviewed 
m [3,7]). Analogously, t-PA activity is strongly stimu- 
lated by binding to fibrm (reviewed m [4-61). 
The activity of u-PA and t-PA IS controlled by two 
types of mhibitors, PAI- and PAI- They belong to the 
serpm superfamily and act by formmg stable eqmmolar 
complexes with the activators PAI-I is the primary m- 
hibitor, being produced by many cell types and present 
m normal blood plasma, while PAI- has a more re- 
stricted occurrence and is a slow mhibitor of t-PA (re- 
viewed m [2,3]) 
The activity of plasmmogen activators is also termi- 
nated by their clearance from the extracellular space by 
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endocytosls and degradation. Clearance may occur lo- 
cally, from cell surfaces or from the perlcellular space m 
the tissues where the activators are produced, or the 
activators may diffuse to blood plasma and be cleared by 
the liver. The total concentrations of u-PA and t-PA m 
normal human plasma 1s around 20 pM and 100 pM, 
respectively; both activators occur mostly m the form of 
complexes with PAI- [8-l 31 Clearance of the activators 
from plasma 1s of pharmacological interest because of 
then use m thrombolytlc therapy (reviewed m [4,6]) 
A number of mvestlgatlons published m 1992 and 
1993 have implicated the cell membrane proteins a,-mac- 
roglobulm receptor/low density hpoprotem receptor-re- 
lated protein (a,MR) and eplthehal glycoprotem 330 
(gp330) m endocytosls and degradation of plasmmogen 
activators and actlvatorlmhlbltor complexes The pur- 
pose of this commumcatlon 1s to review these dlscover- 
les, which have been done m experiments with cell cul- 
tures, and relate them to previous findings concerning 
clearance of plasmmogen activators and actlvator/PAI-1 
complexes m vivo 
2. a,MR and gp330 
The ammo acid sequence of a2h4R was determined m 
two independent ways Herz et al [14] cloned a cDNA, 
which was related to low density hpoprotem receptor by 
its nucleotlde sequence, hence the name LRP, low den- 
sity hpoprotem receptor-related protein a,MR protein 
was purified from rat liver and human placenta, utlhzmg 
its ability to bmd a,-macroglobuhn (a,M)lprotemase 
complexes [15-171 From partial peptlde and cDNA se- 
quences of human placental a,MR, it was found to be 
identical to LRP [ 18,191 a,MR consists of an h4,5 15,000 
hgand bmdmg a-chain and an M, 85,000 membrane 
spanning B-chain, encoded by a single mRNA [20] It 
contams several clusters of three types of modules, of 
which two, the EGF domains and the so-called YWTD 
repeats, were previously found m the EGF precursor, 
and the third m the terminal complement components 
C6-C9 (Fig. 2A). An -Asn-Pro-Xaa-Tyr-sequence m the 
cytoplasmlc tall 1s likely to be essential for endocytosls 
through clathrm-coated pits An A4, 40,000 protein 
(RAP, receptor associated protein) copurlfies with 
aZMR [ 16,171 and mhlblts the bmdmg of all other known 
hgands [21-231 gp330, first identified by KerJaschki and 
Farquhar [24], has been partially sequenced from rat 
sources and shown to be a homologue of a,MR [25] It 
has an M, of more than 500,000 [26]** 
a,MR and gp330 bmd and mediate endocytosls of a 
number of hgands besides plasmmogen activators and 
**The abbreviation gp330 IS dewed from an early determmatlon of the 
M, to 330.000 
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Fig 1 Structural aspects of u-PA, t-PA and u-PAR (A) Schematic 
presentation of the domain structure of u-PA and t-PA (B) SchematIc 
presentation of u-PAR The receptor contams 3 homologous domains, 
the most N-terminal one bmdmg the EGF domam of u-PA 
actlvator/PAI- 1 complexes [21,27-3 l] Although the two 
receptors have many common hgands, mcludmg RAP, 
it 1s noteworthy that gp330 does not bmd a,M/protemase 
complexes [26,30] 
3. a,MR and gp330 bind and internalize u-PAIPAI-1 
complex in cell cultures 
Pro-u-PA and active u-PA bound to u-PAR on cul- 
tured human cells are endocytosed slowly if at all (re- 
viewed m [7]) u-PAR-bound active u-PA is, however, 
susceptible to mhlbltlon by PAI- [32], and m a variety 
of different human cell types, reaction of u-PAR-bound 
u-PA with PAI- leads to rapid degradation of the 
formed complex The degradation can be blocked by 
mhlbltors of lysosomal hydrolases Electron microscopy 
demonstrated endocytosls mto lysosome-like vesicles 
[33-361 The degradation of u-PA/PAI-1 complex 1s 
blocked by RAP and antibodies to a,MR m human mon- 
ocytes [37] and m African green monkey COS kidney 
cells [38]. A RAP-mhlbltable bmdmg of u-PA/PAI-1 
complex to a protein present m membranes from rat and 
rabbit liver and human placenta and comlgratmg with 
a,MR m electrophoresls was demonstrated by a hgand 
blotting assay [28,37-391. u-PA/PAI-1 complex binds to 
lmmoblhzed purified a,MR [37] These findings strongly 
suggest hat a,MR binds and mediates endocytosls of 
u-PAR-bound u-PA/PAI- 1 complex 
u-PA/PAI-1 complex binds to purified rat kidney 
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gp330, and the complex is bound and internalized by 
gp330 m perfused rabbit renal proximal tubules [26] 
4. a,MR and gp330 bind and internalize the t-PA/PAI-1 
complex and t-PA in cell cultures 
Human HepG2 hepatoma cells [4&44], cultured 
smooth muscle cells from human umbilical cord endo- 
thehum [45], cultured human fibroblasts [28], African 
green monkey COS kidney cells and rat H4 hepatoma 
cells [39] bmd and degrade t-PA m a PAI- dependent 
fashion, m the sense that degradation is slow when the 
active site is blocked and that bound t-PA is recovered 
as a complex with PAI- 1. By criteria similar to those used 
for u-PA/PAI-1 complex (see section 3) endocytosis by 
these cells is mediated by a,MR, a,MR preferring t-PA/ 
PAI- complex for uncomplexed t-PA [28,39,44,45] 
u-PAJPAI- 1 complex and t-PA/PAI- 1 complex compete 
for bmdmg to purified a2MR [37], suggesting a common 
bmdmg site. 
Rat MHlCl hepatoma cells bmd and degrade t-PA 
without requirement for accessibihty of the active site 
[46], and m rat H4 hepatoma cells, around 20 percent of 
the t-PA degradation is independent of the active site 
[39] By criteria like those mentioned above, bmdmg and 
degradation is mediated by a,MR in both cases [39,47] 
It appears, therefore, that a,MR can bmd and internalize 
free t-PA m addition to t-PA/PAI-1 complex, at least m 
some rodent cells 
t-PA/PAI-1 complex binds m an RAP-mhibitable 
manner to a rat kidney membrane protem with an elec- 
trophoretic mobility identical to that of gp330 [28], and 
purified gp330 binds t-PA/PAI-1 complex [26], suggest- 
mg that also gp330 can mediate endocytosis of this h- 
gand t-PA/PAI-1 and u-PA/PAI-1 complexes compete 
for bmdmg [26]. 
5. Possible models for in vivo clearance of plasminogen 
activators and activator/inhibitor complexes 
From the cell culture studies described above, m viva 
clearance of u-PAR-bound u-PA/PAI-1 complex from 
cell surfaces appears to be mediated by ol,MR (Fig 3) 
gp330, being expressed m other cell types than a,MR, 
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Fig 2 Structural aspects of a,MR (A) SchematIc presentation of the structure of a,MR a,MR consists of complement type modules (o), EGF 
domains (o), and YWTD repeats (0) The membrane spanmng segment IS marked (I) The site of cleavage at the conversion of the precursor to 
the cc- and the B chain IS marked with an arrow The a-cham contams ammo acid residues I-3920, and the /3-cham contains residues 39254525 of 
the precursor 100 residues at the C-termmus of the /?-chain are locahzed mtracellularly Reproduced from Knstensen et al [18], with permIssIon 
(B) Ammo acid sequence of the hgand bmdmg region m the N-termmal part of a,MR, contammg a cluster of 8 complement-type modules flanked 
by 3 EGF domains and a stretch of YWTD repeats Open boxes mdlcate the complement type modules, and shaded boxes Indicate the flanking EGF 
domams Negatwely charged ammo acids are underlined 
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could have a similar function. It is unknown whether 
u-PAR is endocytosed together with the u-PA/PAI-1 
complex and a,MR (or gp330). The complex could dis- 
sociate from u-PAR concomitantly with the bmdmg to 
a,MR Alternatively, a quarternary complex between 
u-PAR, u-PA, PAI- and a,MR could be internalized. 
If so, it becomes a question whether u-PAR, like a,MR 
[48], is recycled to the cell surface after mtralysosomal 
dissociation of the hgand. Likewise, m viva clearance of 
t-PA and t-PAlPAI-1 complex from the pericellular space 
around producer cells may be mediated by a,MR and 
gp330 
a,MR is expressed m human and rodent liver, m 
human liver, it has been shown to be present m parenchy- 
ma1 cells and Kupffer cells [ 15,491 Is hepatic ol,MR also 
responsible form viva clearance of activators and activa- 
tor/PAI- 1 complexes from blood plasma? 
Human u-PA IS cleared from plasma by the liver when 
injected mtravenously into rodents (reviewed m [ 11) The 
plasma half-life is 0.454 mm Clearance occurs largely 
by uptake mto lysosomes of liver parenchymal cells 
[50,51]. Clearance is not dependent on accessibility of the 
active site [52] The plasma half-life of mtravenously m- 
Jetted human t-PA ranges from 14 mm in rodents to 
5-10 mm m humans. In viva studies with rodents have 
also shown that t-PA accumulates m the liver, where it 
is degraded by lysosomes, and have implicated endothe- 
ha1 cells, parenchymal cells as well as Kupffer cells, ac- 
counting for approximately 45%, 45% and 10% of the 
clearance, respectively. The clearance mechanism of en- 
dothehal cells is mannose dependent, and seems to be 
dependent on the glycosylation site at krmgle 1 The 
clearance mechanism of parenchymal cells is mannose- 
zndependent It requires the finger and growth factor 
domains, but not an available active site Also t-PA/PAI- 
1 complex is cleared by the liver m rodents, and is cleared 
m perfused rat liver (reviewed m [4,6,53-551) For obvi- 
ous reasons, similarly detailed evidence is not available 
for humans 
degradation of t-PA has been found to be mediated by 
the A4, 175,000 mannose receptor [56_60](Fig. 3) Fur- 
thermore, available data are consistent with the assump- 
tion that the mannose zndependent m viva plasma clear- 
ance by liver parenchymal cells mvolves cx,MR (Fig. 3) 
The m viva observations of mannose and active site 
independence and growth factor and finger domain de- 
pendence have been reproduced with cultured rat liver 
parenchymal cells and rodent cell lines of hepatic origin 
[39,46,47,56,58,61-631 Some of these studies have di- 
rectly implicated a,MR, and point to rodent liver ol,MR 
being able to bmd free t-PA as well as t-PA/PAI-1 com- 
plex (see section 4) The experiments with cultured 
human cells consistently point to t-PA/PAI-1 complex 
being endocytosed much faster by a,MR than free t-PA 
(section 4), and the possible role of liver a,MR m m viva 
clearance of free t-PA m humans remains to be studied 
Direct evidence for the mvolvement of a,MR m plasma 
clearance of t-PA m viva is beginning to become availa- 
ble. RAP has recently been found to delay clearance of 
intravenously inJected t-PA in rats [64] 
Endocytosis of preformed u-PA/PAI-1 complex by 
monocytes is strongly mhibited by an N-terminal frag- 
ment of u-PA, which blocks its bmdmg to u-PAR, but 
A / 3 
t-PA 
C 
Attempting to correlate these m viva data with the 
findings with cell cultures, assumption of liver parenchy- 
ma1 cell ol,MR being an mdispensable part of the m viva 
mechanism for plasma clearance of u-PA/PAZ-l complex 
IS seen to be m agreement with the published m vitro 
bmdmg studies with rat and rabbit liver membrane pro- 
teins and the data on human cell lines (see section 3). 
These data suggest hat a,MR-mediated plasma clear- 
ance of u-PA is greatly accelerated after complex forma- 
tion with PAI- 1, and plasma clearance mechanisms for 
free u-PA remam to be characterized Cultured rat liver 
parenchymal cells do bmd and degrade u-PA [50,51], but 
it has not been shown that a,MR is mvolved. 
PAI- 
t-PA 
MR 
t-PA 
With respect to t-PA, the mannose dependence of m 
viva plasma clearance by rodent liver endothehal cells is 
m agreement with studies with cultured rat liver endothe- 
ha1 cells, m which bmdmg, endocytosis and lysosomal 
Fig 3 Cartoon showing models for a,MR-medlated clearance of (A) 
u-PAR-bound u-PA/PAI-1 complexes from the surface of hver par- 
enchymal cells or extrahepatlc ells, (B) mannose receptor-medlated 
clearance of t-PA by liver endothehal cells, (C) a,MR-mediated clear- 
ance of t-PAE’AI-1 complexes and free t-PA by hver parenchymal cells 
or by extrahepatlc ells, with the hypothetlcal mvolvement of a t-PA 
receptor a,MR and mannose receptor are drawn as situated m coated 
pits 
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not to ol,MR [37]. This is likely to be caused by a faster 
association to a,MR of u-PAR-bound complex than of 
complex free in solution, u-PAR binding creating a local 
high concentration of complex on the cell surface. Simt- 
larly, hepatic u-PAR may serve to accelerate clearance of 
u-PA/PAI- 1 complex from plasma by concentrating it on 
liver cell surfaces and presenting it to ol,MR Additional 
bmdmg proteins could be involved m concentrating acti- 
vators and activator/PAI-1 complexes on liver cell sur- 
faces, for instance putative dtstmct rodent hepattc u-PA 
bmdmg proteins [50,51] and putative hepatic t-PA and 
t-PA/PAI-1 receptors [62,63,65] (Fig. 3). Other t-PA 
bmdmg protems [66-681 may have smrtlar functions m 
clearance from the pencellular space m extrahepatic tissues. 
It should be noted that the various m viva clearance 
studies referred to above have been done with highly 
variable amounts of activator being injected mtrave- 
nously, m many cases leading to plasma concentrations 
far above physiological ones and far m excess of plasma 
PAI- concentrations. Although the use of such high 
concentrations are relevant to the pharmacologzcal situa- 
tion during thrombolytic therapy, it may not necessarily 
give results that are relevant for evaluatmg the relative 
importance of different receptor systems m m vwo clear- 
ance of physzologzcal activator concentrations. A further 
complicating factor is the use of human u-PA m rodents, 
rodent u-PAR binds human u-PA with only a low affinity 
[71 
6. Structural aspects of plasminogen activator and 
activator/PAI-1 complex binding to a,MR and gp330 
Like other hgands, activator/PAI-1 complexes and 
t-PA bmd to the cc-chain of a,MR [37,39,47] The bmd- 
mg 1s dependent on Ca2’ [37-391. u-PA/PAI-1 complex, 
azM/protemase complexes and RAP have been shown to 
bmd to a region m the N-termmal part of ol,MR, con- 
taming a cluster of eight complement-type modules, 
flanked N-termmally by one EGF-domain and C-termi- 
nally by two EGF-domains and a stretch of YWTD- 
repeats [69] (see Fig 2). The bmdmg sites for other h- 
gands have not been localized within the a-chain, and 
a,MR and gp330 have more than one bmdmg site for 
RAP [23,26] 
In most studies, activator/PAI-1 complexes have been 
found to bmd to a,MR and gp330 with higher affinity 
than each moiety alone [26,28,37,39]. Some observations 
suggests that the activator moiety as well as the inhibitor 
moiety make contact with a,MR. free u-PA and free 
PAI- inhibit the bmdmg of u-PA/PAI-1 complex to 
a,MR with a low affinity, and u-PA/PAI-1 complex 
bmdmg is inhibited by monoclonal antibodies against 
u-PA as well as against PAI- [37] Thus, the higher 
affinity of activator/PAI-1 complexes, as compared to 
each component alone, may be due to the receptors mak- 
mg contacts to both moieties. The A-chain as well as the 
serme protemase domain of u-PA and t-PA (Fig. 1A) 
seem to be involved in binding. Thus, studies of PAI- 
and cr,MR dependent endocytosis of t-PA by vascular 
smooth muscle cells led to the finding that a t-PA mutant 
lacking the finger and growth factor domain was endocy- 
tosed less efficiently than wild-type t-PA [45]. Substitu- 
tion m t-PA of Tyr-67 with Asn created a new N-linked 
glycosylation site m the growth factor domain; this sub- 
stttution delayed degradation of t-PA by H4 rat 
hepatoma cells [70], which is mediated by a,MR [39] 
None of these mutations affected the reaction with PAI- 
1 One possible mterpretation of these findings is that the 
mentioned domains are involved m t-PA/a,MR contacts, 
but the findings need to be confirmed with purified 
a,MR, as other receptors may be involved m endocytosis 
(see section 5) Recent experiments with purified a,MR, 
a complex between PAI- and the M, 30,000 degradation 
product of u-PA, which lacks the growth factor domain 
and the krmgle, and with monoclonal anti-u-PA and 
anti-PAI- antibodies with known epitopes further sup- 
port a bmdmg mechanism with multiple independent 
contacts between u-PA/PAI-1 complex and a,MR [71]. 
t-PA degradation by the rat hepatoma cell lme 
MHlCl is PAI- independent, m contrast to degrada- 
tion by human HepG2 hepatoma cells and around 80 
percent of the degradation by the rat H4 hepatoma cells 
(see section 4). This is not due to major differences m 
PAI- production between the cell lines [46] Taken at 
face value, this observation suggests that a,MR m 
MH 1Cl cells has a relatively higher affinity to uncom- 
plexed t-PA, as compared to t-PA/PAI-1 complex, than 
ol,MR m the other cells It may be speculated that bmd- 
mg spectficny of a,MR is rendered cell-specific through 
differential sphcmg and/or post-translational modifica- 
tions 
There is no universal cross-competition between the 
many hgands, for instance, ol,Mlprotemase complexes 
and u-PA/PAI-1 complex do not compete for bmdmg to 
a,MR [37], m spite of the fact that these two sets of 
hgands bmd to the same region of the receptor (see 
above) Neither are there any obvious common struc- 
tural motifs m the many hgands to a,MR and gp330. It 
is noteworthy, however, that bmdmg of many hgands, 
mcludmg u-PA/PAI-1 complex, is mhibited by heparm 
Heparm does not bmd to a,MR [21], and the strongly 
negatively charged heparm could act by bmdmg to posi- 
tive charges on the hgands Bmdmg of a,M/protemase 
complexes is not inhibited by heparm [21], but denvati- 
zation of lysme residues in the human &,M receptor 
bmdmg domain destroys receptor bmdmg [72,73] The 
complement-type modules m the region implicated m 
hgand bmdmg m ol,MR (see above) is rich m negatively 
charged residues (Fig. 2B). Ligand/receptor bmdmg may 
thus depend on mteraction, m a hydrophobic envnon- 
ment, between these negative charges and properly posi- 
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tioned positive charges on the surface of the hgands. The 
many negative charges may contribute to endowing this 
region, and putative other hgand bmdmg regions, with 
a highly versatile hgand bmdmg ability Heparm binds 
to the u-PA krmgle [74] and to PAI- [75] The increased 
affinity of actrvator/PAI-1 complexes, as compared to 
each component alone, may be due to complex forma- 
tion posttionmg groups of positive charges optimally for 
receptor bmdmg 
7. Perspectives 
The findings described here have important tmphca- 
tions for our understanding of the plasmmogen actrva- 
tion system. a,MR and gp330 mediated clearance of 
u-PAIPAI-1 complex from cell surfaces may be of func- 
tional importance for the u-PA-dependent pathway of 
plasmmogen activation Serine protemase enzyme sys- 
tems generally function by the sequential activation of 
zymogens, a period of activity of the active enzyme, and 
reaction with mhibitors [76] Contmued activity there- 
fore depends on continued activation of the zymogens 
Without clearance, u-PA/PAI-1 complex could accumu- 
late and occupy the u-PAR-sites that are necessary for 
an efficient conversion of pro-u-PA to u-PA and subse- 
quent u-PA catalysed plasmmogen actrvation. Some cells 
are unable to degrade u-PAR-bound u-PAIPAI-1 com- 
plex, presumably due to lack of clearance receptors [35], 
future studies should reveal whether this results m a 
shorter duration of cell-surface-organized plasmmogen 
activation 
The findings also show aspects that are novel to cell 
biology and biochemistry m general The great versatility 
m high affinity hgand bmdmg exhibited by a2MR and 
gp330 is unusual m receptor biochemistry The bmdmg 
of plasmmogen activators and activator/mhibitor com- 
plexes to ol,MR and gp330 represents a new type of 
molecular recognition of serme protemases and serpms 
Further studies of its structural basis by the use of mut- 
agenesis, chemical crosshnkmg and determmation of 
three-dtmensional structures are highly desirable Gener- 
ally, mternahzation of GPI-anchored membrane pro- 
teins does not seem to follow the classical clathrm-coated 
pit pathway (reviewed m [77]). Some GPI-anchored pro- 
teins have been reported to be endocytosed via non- 
coated mvagmations, so-called caveolae (reviewed m 
[78]) The a,MR and gp330 mediated endocytosts of the 
hgands mitially bound to u-PAR is an alternative mode 
of endocytosis of hgands to GPI-anchored receptors, 
and perhaps of GPI-anchored receptors themselves 
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